Patent receives dental implant award

Patent Medical

Fri. 10. October 2025

save

FORT LAUDERDALE, Fla., US: Swiss dental implant specialist Patent Medical has been named “Dental Implants Manufacturer of the Year in Europe” by MedTech Outlook. The award recognises Patent as the first implant system to achieve a scientifically proven bond between peri-implant soft tissue and a transmucosal implant surface—an advancement regarded as a decisive breakthrough in the field of dental implantology.

MedTech Outlook is a leading US-based trade magazine that provides in-depth coverage of advances in medical technology. The magazine honours companies developing disruptive medical technologies, and its recognition of Patent’s implant system acknowledges the company’s significant contribution to the prevention of peri-implantitis.

Soft-tissue bond to prevent peri-implantitis

The Patent dental implant system has demonstrated a bond between peri-implant mucosa and a synthetic surface—a first in the history of dentistry. A research team led by Prof. Anton Sculean, Dr Peter Schüpbach, Dr Roland Glauser and Prof. Dieter Bosshardt confirmed this novel biomechanical cell bond in histological investigations.

Histology of a Patent implant (left) four weeks after insertion; thanks to the soft-tissue bond with the transmucosal implant surface (red circle), no plaque is visible below the soft-tissue level. (Image: Dr Peter Schüpbach)

Patent implants undergo a proprietary surface treatment that imparts mucophilic and cell-occlusive properties—enhancing soft-tissue integration and creating a barrier to bacterial ingress—as well as a surface topography modelled on natural tooth structure. As a result, epithelial cells begin to grow on to the transmucosal Patent surface already in the early stages of healing, ultimately establishing a bond with it.

At EuroPerio11 in Vienna in Austria, where these histological results were presented during a symposium, Dr Glauser emphasised that the soft-tissue bond to the transmucosal Patent surface functions as a dynamic protective barrier that stops plaque from migrating downwards into the tissue and thereby protects it from bacterial invasion. Consequently, the risk of inflammation and tissue recession is greatly reduced, progression from mucositis to peri-implantitis is prevented, and stable aesthetics are maintained long term.

Peri-implantitis prevented in long-term studies

The efficacy of this soft-tissue bond has been demonstrated in long-term studies. Research conducted at universities in Germany and Austria followed two-piece Patent implants for up to nine and 12 years, respectively. The results showed no cases of peri-implantitis, even in high-risk patients with periodontitis or systemic diseases such as cancer, diabetes or multiple sclerosis or in patients with poor oral hygiene or smoking habits. A detailed report is available on the MedTech Outlook website.